VBL Therapeutics
6 Jonathan Netanyahu Street
Or Yehuda
60376
Tel: 97-236-346450
Fax: 97-236-346449
Website: http://www.vblrx.com/
Email: businessdev@vbl.co.il
209 articles about VBL Therapeutics
-
VBL Therapeutics Data On VB-111 In Combination With Bevacizumab To Be Presented At The Annual Meeting Of The Society For Neuro-Oncology
11/16/2015
-
VBL Therapeutics Announces Third Quarter 2015 Financial Results And Provides Business Update
11/12/2015
-
VBL Therapeutics To Report Third Quarter 2015 Financial Results On November 12
11/5/2015
-
VBL Therapeutics Presents Positive Data On VB-111 In Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer At The ITC 2015 Conference
10/22/2015
-
VBL Therapeutics Reports Full Phase 2 Data From Clinical Trial Of VB-111 In Recurrent Glioblastoma (rGBM) At The ECC 2015 Conference, Meeting The Primary Endpoint Of Statistically-Significant Increase In Overall Survival
9/28/2015
-
VBL Therapeutics To Present Complete Phase 2 Data On VB-111 In Combination With Bevacizumab In Recurrent GBM At The European Cancer Conference
9/18/2015
-
VBL Therapeutics Announces First Patient Dosed In Pivotal Phase III Trial Of VB-111 In Recurrent Glioblastoma
8/20/2015
-
VBL Therapeutics Announces Second Quarter 2015 Financial Results And Provides Business Update
8/13/2015
-
VBL Therapeutics To Report Second Quarter 2015 Financial Results On August 13, 2015
8/6/2015
-
VBL Therapeutics To Present Data On Proprietary Gene Therapy Vascular Targeting System And Lead Product VB-111 - At Drug Discovery And Therapy World Congress 2015
7/14/2015
-
ASCO15: VBL Therapeutics To Present Phase I/IIa Data From VB-111 In Recurrent Platinum-Resistant Mullerian Cancer At The 2015 ASCO Annual Meeting
6/1/2015
-
ASCO15: VBL Therapeutics Reports Updated Interim Results From Phase II Clinical Trial Of VB-111 In Recurrent Glioblastoma (Rgbm)
6/1/2015
-
VBL Therapeutics To Webcast Analyst And Investor Event At ASCO Annual Meeting On June 1, 2015
5/26/2015
-
VBL Therapeutics To Present Positive Phase I/II Data For VB-111 In Recurrent Platinum-Resistant Mullerian Cancer At ASCO Annual Meeting
5/14/2015
-
VBL Therapeutics Announces First Quarter 2015 Financial Results
5/12/2015
-
VBL Therapeutics To Report First Quarter 2015 Financial Results On May 12, 2015
5/5/2015
-
VBL Therapeutics To Present Company Overview At Upcoming Conferences In May
4/30/2015
-
VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial Of VB-111 In Recurrent Glioblastoma (Rgbm)
3/25/2015
-
VBL Therapeutics Announces Fourth Quarter And Full Year 2014 Financial Results
3/25/2015
-
VBL Therapeutics To Report Fourth Quarter And Full Year 2014 Financial Results On March 25, 2015
3/20/2015